Drug General Information (ID: DDI0V21HBG)
  Drug Name Interferon gamma-1b Drug Info Baricitinib Drug Info
  Drug Type Interferons Small molecule
  Therapeutic Class Immunomodulatory Agents Antirheumatics

 Mechanism of Interferon gamma-1b-Baricitinib Interaction (Severity Level: Major)
     Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Interferon gamma-1b Baricitinib
      Mechanism Immunosuppressive effects Immunosuppressive effects
      Key Mechanism Factor 1
Factor Name Immunosuppressive effects
Factor Description Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
      Mechanism Description
  • Additive immunosuppressive effects by the combination of Interferon gamma-1b and Baricitinib 

Recommended Action
      Management Close monitoring for the development of infection is recommended if baricitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and baricitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, baricitinib should be interrupted until the infection is controlled.

References
1 Cerner Multum, Inc. "Australian Product Information.".
2 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3 Product Information. Olumiant (baricitinib). Lilly, Eli and Company, Indianapolis, IN.